Case Based Panel Discussion 2.5 Progression After ALK Inhibitors Is There a Role for Combination Therapies episode artwork

EPISODE · May 20, 2020 · 11 MIN

Case Based Panel Discussion 2.5 Progression After ALK Inhibitors Is There a Role for Combination Therapies

from GRACEcast - Discussions with the Global Resource for Advancing Cancer Education · host cancerGRACE

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, they discuss progression after success on Alk inhibitors, and if there is a role for combination therapies like chemo/Avastin and immunotherapy.

Episode metadata supplied by the publisher feed · Published May 20, 2020

Embed this episode

NOW PLAYING

Case Based Panel Discussion 2.5 Progression After ALK Inhibitors Is There a Role for Combination Therapies

0:00 11:54

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of GRACEcast - Discussions with the Global Resource for Advancing Cancer Education?

This episode is 11 minutes long.

When was this GRACEcast - Discussions with the Global Resource for Advancing Cancer Education episode published?

This episode was published on May 20, 2020.

Can I download this GRACEcast - Discussions with the Global Resource for Advancing Cancer Education episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!